Researchers have found that Molecular Breast Imaging (MBI) provides an Incremental Cancer Detection Rate (ICDR) over mammography per 1000 woman with dense breast screened. Rhodes et al. AJR 2015
CARLSBAD, Cali. (PRWEB) September 28, 2020
Published in the AJR August 2020 edition, the purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and clarify radiation risks.
Authors Elizabeth H. Dibble, Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, and Katie N. Hunt, Eric C. Ehman, Michael K. O’Connor, Department of Radiology, Mayo Clinic, concluded that MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice.
Read More: https://www.ajronline.org/doi/abs/10.2214/AJR.19.22622
CMR Molecular Imaging manufactures and commercializes the LumaGEM ® MBI system, with dual-head digital direct conversion gamma imaging, that provides high resolution images with less than 2 mm resolution, using a low dose of Tc99 Sestamibi radiotracer. With over 90 percent sensitivity and specificity, LumaGEM MBI® has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.
Researchers have found and published data demonstrating that in women with dense breast tissue, MBI detects an additional 8.8 cancers per 1000 women screened providing an incremental cancer detection rate (ICDR) of 250% over mammography. Rhodes et al. AJR 2015
About CMR Molecular Imaging: CMR Molecular Imaging is a unit of CMR Naviscan Corporation, a leader in organ-specific molecular imaging and part of the Compañia Mexicana de Radiologia CGR, S.A. de C.V. (CMR), a global developer and manufacturer of high quality diagnostic imaging equipment and healthcare information systems, including DICOM-compliant imaging software. CMR Naviscan, headquartered in Carlsbad, California, develops and manufactures molecular imaging systems, including the Solo II™ High Resolution Breast PET Imaging (BPI) scanner, the Stereo Navigator® Biopsy Guidance Accessory, and the LumaGEM® Molecular Breast Imaging (MBI) system. CMR Naviscan is US FDA registered and ISO 13485:2012 certified.
For more information visit http://www.cmr-naviscan.com